Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CureVac N.V. - Ordinary Shares
(NQ:
CVAC
)
5.240
-0.250 (-4.55%)
Streaming Delayed Price
Updated: 1:17 PM EST, Dec 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about CureVac N.V. - Ordinary Shares
< Previous
1
2
3
4
Next >
CureVac Announces Voting Results of Extraordinary General Meeting
November 25, 2025
Via
ACCESS Newswire
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
November 24, 2025
Via
ACCESS Newswire
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
August 15, 2025
Via
ACCESS Newswire
CureVac Announces Voting Results of General Meeting
June 24, 2025
Via
ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders
June 20, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators
February 18, 2025
Via
ACCESS Newswire
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
November 12, 2024
Via
ACCESSWIRE
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
June 13, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
June 13, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
November 04, 2024
Via
ACCESSWIRE
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
September 12, 2024
Via
ACCESSWIRE
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
August 15, 2024
Via
ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
August 15, 2024
Via
ACCESSWIRE
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
June 12, 2025
From
Halper Sadeh LLC
Via
Business Wire
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
May 20, 2025
Via
ACCESS Newswire
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
May 15, 2025
Via
ACCESS Newswire
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
April 10, 2025
Via
ACCESS Newswire
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
April 08, 2025
Via
ACCESS Newswire
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
July 11, 2024
Via
ACCESSWIRE
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
July 03, 2024
Via
ACCESSWIRE
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
April 07, 2025
Via
ACCESS Newswire
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
March 27, 2025
Via
ACCESS Newswire
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
November 07, 2024
Via
ACCESSWIRE
CureVac to Present at the 12th International mRNA Health Conference
November 04, 2024
Via
ACCESSWIRE
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 28, 2024
Via
ACCESSWIRE
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
September 13, 2024
Via
ACCESSWIRE
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
September 09, 2024
Via
ACCESSWIRE
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
August 15, 2024
Via
ACCESSWIRE
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
July 02, 2024
Via
ACCESSWIRE
CureVac Announces Voting Results of General Meeting
June 24, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
